DURHAM, N.C., Dec. 2, 2013 /PRNewswire/ -- Scioderm, Inc. announced the appointment of John Crowley and William Aliski to the company's Board of Directors.
As Chairman & CEO of NASDAQ listed Amicus Therapeutics, John brings a significant rare and orphan disease experience to Scioderm, in addition to his in depth transactional and public sector market experience. His personal drive, commitment and overall determination to find cures for rare diseases such as Pompe and Fabry Disease will substantially contribute to the overall success of Scioderm.
William (Bill) Aliski brings over 25 years of senior executive orphan drug commercial management experience most recently with FoldRx Pharmaceuticals, Inc. Prior to that he was General Manager for Biomarin Europe and directed the launch of Naglazyme for MPS VI. He has played a critical leadership role in the launch of other orphan products having spearheaded market access and pricing strategies for companies such as Genzyme and TKT.
"I am most pleased to join the Board of Scioderm and to support the company in its realization of its mission and objectives for its lead orphan pediatric product SD-101 for the treatment of all subtypes of Epidermolysis Bullosa, a rare and debilitating pediatric disease," noted John Crowley. "I hope that my experience and perspectives in the orphan drug space can contribute to ensuring the rapid and successful development of this exciting new compound for people living with EB."
Bill Aliski commented, "I look forwarded to working with the management and Board of Scioderm particularly in supporting the company with the definition and execution of its global commercialization strategy including market access and pricing for its epidermolysis bullosa progr
Copyright©2012 PR Newswire.
All rights reserved